We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Watson Pharmaceuticals and Andrx have extended their merger deadline an additional two months to address the FTC’s review of the transaction, the companies said.
Abbott Laboratories and AstraZeneca will collaborate on the development and marketing of a combination treatment targeting three blood lipids – LDL “bad” cholesterol, HDL “good” cholesterol, and triglycerides — in a single pill.
Pfizer will sell its consumer healthcare division to Johnson & Johnson (J&J) for $16.6 billion and focus on developing new drugs and acquiring new technology, according to announcements by both companies.
Schering-Plough will establish Schering-Plough Produtos Farmaceuticos Limitada, a wholly owned operation based in Sao Paulo, Brazil, to market its core products, and will restructure its agreement with Brazilian drugmaker Mantefarma as part of its effort to increase its presence in Latin America, the company announced.
Ranbaxy Netherlands BV has acquired a 96.7 percent stake in the Romanian pharmaceutical company Terapia, the company announced. The $324 million acquisition follows approval by the Romanian Competition Council.
Israel-based drugmaker CureTech has finalized an agreement in which Teva Pharmaceutical has received an option to invest $22 million in the company, in addition to a $6 million investment announced several months ago.
HHS’ Office of Inspector General (OIG) has entered into a settlement agreement and corporate integrity agreement (CIA) with Lincare Holdings and its subsidiary Lincare, the agency announced May 15.